Shots:
- The US FDA has cleared Novaliq’s IND application for NOV05, enabling initiation of the EYETAC P-II clinical study in pts with non-infectious anterior uveitis (NIAU)
- The EYETAC P-II study will be conducted in the US and is expected to begin in Q1’26, evaluating the safety, tolerability, and dose-dependent anti-inflammatory effects of NOV05
- NOV05 is a steroid-free tacrolimus ophthalmic solution formulated in Novaliq’s EyeSol platform and is designed to deliver drug topically to inner-eye tissues, addressing limitations of current corticosteroid-based therapies
Ref: Novaliq | Image: Novaliq | Press Release
Related News: Novaliq’s Vevizye (Ciclosporin) gains the CHMP’s Positive Opinion to Prevent Moderate to Severe Dry Eye Disease (DED)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
